Skip to main content
SpringerLink
Log in

Effect of Hormones on Established Prostatic Hypertrophy

  • Chapter
Benign Prostatic Hypertrophy

  • 24 Accesses

Abstract

The frequency of bladder outlet obstructive symptoms in Caucasion men over age 50 approaches 50–75%,29 and microscopic cellular hyperplasia resulting from a second prostatic growth spurt14 may be documented in 75% of men by age 90.3 The inconsistent relationship between degree of prostatic hyperplasia and development of symptoms6 has been related to fibroadenomatous nodule formation resulting from periurethral mesenchymal stimulation interacting with epithelial proliferation.7 McNeal14 described a “transition zone” of perisphincter tissue that may represent a specific site of origin of benign prostatic hypertrophy (BPH) (Fig. 1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beeson PB, McDermott W, Wyngaarden JB: Cecil Textbook of Medicine, 15th ed. Saunders, Philadelphia, 1979

    Google Scholar 

  2. Berg OA: The normal prostate gland of the dog. Acta Endocrinol (Copenh) 27: 129–139, 1958

    CAS  Google Scholar 

  3. Brendler HE: Benign prostatic hyperplasia: natural history. In Grayhack JT, Wilson JD, Scherbenske MJ (eds.): Benign Prostatic Hyperplasia, DHEW Publ. No. (NIH)76-1113, US Gov’t Printing Office, Washington, DC, 1976, pp 101–103

    Google Scholar 

  4. Caine M, Perlberg S, Gordon R: The treatment of BPH with flutamide (SCH 13521): a placebo controlled study. J Urol 114: 564–568, 1975

    PubMed  CAS  Google Scholar 

  5. Castro JE, Griffiths HJ, Edwards DE: A double-blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy. Br J Surg 58: 485–489, 1971

    Article  PubMed  CAS  Google Scholar 

  6. DeKernion JB, Richie JP, Olsson CA, Webster GD, Devine CJ, Donohue JP, Retik AB: In Paulson DF (ed.): Operative Urology. Churchill Livingstone, New York, in press, 1982

    Google Scholar 

  7. Franks LM: Gross and microscopic anatomy. In Grayhack JT, Wilson JD, Scherbenske MJ (eds.): Benign Prostatic Hyperplasia. DHEW Publ. No. (NIH)76-1113, US Gov’t Printing Office, Wash-ington, DC, 1976, p 63–89

    Google Scholar 

  8. Geller J, Angrist A, Nakao K, Newman H: Therapy with progestational agents in advanced benign prostatic hypertrophy. JAMA 210: 1421–1427, 1969

    Article  PubMed  CAS  Google Scholar 

  9. Geller J, Bora R, Roberts T, Newman H, Lin A, Silva R: Treatment of benign prostatic hypertrophy with hydroxyprogesterone caproate. JAMA 193: 115–122, 1965

    Google Scholar 

  10. Gittes RF, McLaughlin AP: Experimental approaches to BPH: implants of BPH in immunosup-pressed animals. In Grayhack JT, Wilson JD, Scherbenske MJ (eds.): DHEW Publ. No. (NIH)76-1113, US Gov’t Printing Office, Washington, DC, 1976, pp 263 - 268

    Google Scholar 

  11. Huggins CJ, Stevens RA: Effect of castration on BPH of the prostate of man. J Urol 43: 705–714, 1940

    Google Scholar 

  12. Kaufman JJ, Goodwin WE: Hormonal management of the benign obstructing prostate use of combined androgenestrogen therapy. J Urol 81: 165–171, 1959

    PubMed  CAS  Google Scholar 

  13. Lesser MA, Vose SN, Dixey GM: Effect of testosterone propionate on the prostate gland of patients over 45. J Clin Endocrinol Metab 15: 297–300, 1954

    Article  Google Scholar 

  14. McNeal J: Origin and evolution of benign prostatic enlargement. Invest Urol 15: 340–345, 1978

    PubMed  CAS  Google Scholar 

  15. Paulson DF, Kane RD: Medrogestone: a prospective study in the pharmaceutical management of benign prostatic hyperplasia. J Urol 113: 811–815, 1975

    PubMed  CAS  Google Scholar 

  16. Peirson EL: A study of the effect of stilbestrol therapy on the size of the benignly hypertrophied prostate gland. J Urol 49: 73–78, 1946

    Google Scholar 

  17. Rangno RE, McLeod PJ, Ruedy J, Ogilvie RI: Treatment of benign prostatic hypertrophy with medrogestone. Clin Pharmacol Ther 12: 658–665, 1971

    PubMed  CAS  Google Scholar 

  18. Scott WW, Coffey DS: Nonsurgical treatment of human benign prostatic hyperplasia. Vitam Horm 33: 439–465, 1975

    Article  PubMed  CAS  Google Scholar 

  19. Scott WW, de Klerk DP: Benign prostatic hyperplasia: current status of medical treatment. In Gray hack JT, Wilson JD, Scherbenske MJ (eds.): Benign Prostatic Hypertrophy. DHEW Publ. No. (NIH)76-1113, US Gov’t Printing Office, Washington, DC, 1976, p 135–151

    Google Scholar 

  20. Scott WW, Wade JC: Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate. J Urol 101: 81–85, 1969

    PubMed  CAS  Google Scholar 

  21. Siiteri PK, Wilson JD: Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest 49: 1737–1745, 1970

    Article  PubMed  CAS  Google Scholar 

  22. Tveter AJ: Some aspects of the pathogenesis of prostatic hyperplasia. Acta Pathol Biol Scand [Suppl] 248: 167–174, 1974

    Google Scholar 

  23. Vermeulen A: Testicular hormonal secretion and aging in males. In Grayhack JT, Wilson JD, Scherbenske MJ (eds.): Benign Prostatic Hypertrophy, DHEW Publ. No. (NIH)76-1113, US Gov’t Printing Office, Washington, DC, 1976, pp 177–183

    Google Scholar 

  24. Walsh P: Experimental approaches to benign prostatic hypertrophy in animal models utilizing the dog, rat and mouse. In Grayhack JT, Wilson JD, Scherbenske MJ (eds.): Benign Prostatic Hypertrophy. DHEW Publ. No. (NIH)76-1113, US Gov’t Printing Office, Washington, DC, 1976, p 215–222

    Google Scholar 

  25. Walsh P, Wilson G: The induction of prostate hypertrophy in the dog with androstandediol. J Clin Invest 57: 1093–1097, 1976

    Article  PubMed  CAS  Google Scholar 

  26. Wendel EF, Brannen GE, Putong PB, Grayhack JT: The effect of orchiectomy and estrogens on benign prostatic hyperplasia. J Urol 108: 116–119, 1972

    PubMed  CAS  Google Scholar 

  27. White JW: The results of double castration in hypertrophy of the prostate bladder. Am Surg 22: 1, 1895

    CAS  Google Scholar 

  28. Williams G, Ghanadian R, Castro JE: The growth and viability of human prostatic tissue maintained in immunosuppressed mice. Clin Oncol 4: 347–351, 1978

    PubMed  CAS  Google Scholar 

  29. Wilson JD: The pathogenesis of benign prostatic hyperplasia. Am J Med 68: 745–756, 1980

    Article  PubMed  CAS  Google Scholar 

  30. Wilson G, Walsh P: Studies on the pathogenesis of benign prostatic hypertrophy in the dog. In Grayhack JT, Wilson JD, Scherbenske (eds.): Benign Prostatic Hypertrophy. DHEW Publ. No. (NIH)76-1113, US Gov’t Printing Office, Washington, DC, 1976, p 205–213

    Google Scholar 

  31. Wolf H, Madsen PO: Treatment of benign prostatic hypertrophy with progestational agents: a preliminary report. J Urol 99: 780–785, 1968

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Sigmund I. Tannenbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David F. Paulson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, University of California, San Francisco, San Francisco, California, 94143, USA

    Frank Hinman Jr. (Clinical Professor of Urology) (Clinical Professor of Urology)

  2. Department of Surgery, Division of Urology, Washington University School of Medicine, St. Louis, Missouri, 63110, USA

    Saul Boyarsky M.D., J.D., F.A.C.S. (Professor of Genitourinary Surgery and Biomedical Engineering) (Professor of Genitourinary Surgery and Biomedical Engineering)

Rights and permissions

Reprints and permissions

Copyright information

© 1983 Springer-Verlag New York Inc.

About this chapter

Cite this chapter

Tannenbaum, S.I., Paulson, D.F. (1983). Effect of Hormones on Established Prostatic Hypertrophy. In: Hinman, F., Boyarsky, S. (eds) Benign Prostatic Hypertrophy. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-5476-8_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-5476-8_23

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-5478-2

  • Online ISBN: 978-1-4612-5476-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation